When should F-18 FDG PET/CT be used instead of 68Ga-DOTA- peptides to investigate metastatic neuroendocrine tumors?

Clinical Nuclear Medicine

Volumn 36, Issue 12, 2011, Pages 1109-1111

  Fuccio, Chiara ^a   Musto, Alessandra ^b,c   Cambioli, Silvia ^a   Castellucci, Paolo ^a   Pantaleo, Maria A ^a   Nanni, Cristina ^a   Montini, Gian C ^a   Campana, Davide ^a   Tomassetti, Paolo ^a   Bellan, Elena ^b,c   Massaro, Arianna ^b,c   Grassetto, Gaia ^b,c   Rubello, Domenico ^b,c   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

68Ga DOTA NOC; aggressive NETs; F 18 FDG; management; PET CT

Indexed keywords

(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID) 1 NAL3 OCREOTIDE GALLIUM 68; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; KI 67 ANTIGEN; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISORDERS OF CARBOHYDRATE METABOLISM; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER METASTASIS; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PROGNOSIS; SYSTEMIC THERAPY;

AGED; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER; MALE; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 80955139441     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823361f7     Document Type: Article

References (8)

1. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79-83. (Pubitemid 28107907)
2. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for 90YDOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-466.
3. Koukouraki S, Strauss LG, Georgoulias V, et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and 18-F-FDG in patients with metastatic neuroendocrine tumor scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122. (Pubitemid 44484467)
4. Pasquali C, Rubello D, Sperti C, et al. NET tumor imaging: Can 18Ffluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588-592. (Pubitemid 28215437)
5. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16. (Pubitemid 40695259)
6. Krenning EP, Valkema R, Kwekkeboom DJ, et al. Molecular imaging as in vivo molecular pathology for gastroenterohepatic neuroendocrine tumors: Implications for follow-up after therapy. J Nucl Med. 2005;46(suppl 1):76S- 82S. (Pubitemid 47619022)
7. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
8. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3- octreotate) and 18F-FDG. Cancer. 2008;112:2447-2455.